ArticleThe Journal of pathology2016
Uterine adenosarcomas are mesenchymal neoplasms.
Article in The Journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Uterine lesions with sex cord-like architectures: a systematic review.Diagnostic pathology · 2019Pooled it
- Article
- ESR1::NCOA2/3 fusions in uterine neoplasms with adenosarcoma-like morphology: clinicopathologic and molecular features of 12 cases and review of the literature.Virchows Archiv : an international journal of pathology · 2026Article
- A case report of uterine adenosarcoma with sarcomatous overgrowth and pulmonary metastasis.Frontiers in oncology · 2026Article
- A Novel Odontogenic Carcinoma with CDK4/MDM2 Co-Amplification: Expanding the Phenotypic Spectrum of Malignant Odontogenic Entities.Head and neck pathology · 2025Article
- Pelvic spindle cell sarcomas harboring MEIS1::NCOA2 fusion and novel gene amplifications in 10q23-26 region: a potential predictor for tumor progression.Virchows Archiv : an international journal of pathology · 2025Article
- Clinicopathological Comparison BetweenDiagnostics (Basel, Switzerland) · 2025Review
- Uterine Adenomyosarcoma Complicated by Uterine Prolapse and Necrosis: A Case Report.International medical case reports journal · 2025Article
- Botryoid-type Embryonal Rhabdomyosarcoma: A Comprehensive Clinicopathologic and Molecular Appraisal With Cross-comparison to its Conventional-type Counterpart.The American journal of surgical pathology · 2024Article
- p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review).Oncology letters · 2024Review
- Clinicopathological analysis of 22 Müllerian adenosarcomas and the sequencing of DICER1 mutation.Diagnostic pathology · 2024Article
- Highly Sensitive Detection of PIK3CA Mutations by Looping-Out Probes-Based Melting Curve Analysis.Biochemical genetics · 2024Article
- The Pathology according to p53 Pathway.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024Review
- Case report: An atypical case of uterine adenosarcoma with extensive bizarre stromal cells and amplification of MDM2.Frontiers in oncology · 2024Article
- Intravenous metastasis of unexpected uterine sarcoma in the context of uterine fibroids: case report and literature review.Frontiers in oncology · 2024Article
- "PRRX1-rearranged mesenchymal tumors": expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature.Virchows Archiv : an international journal of pathology · 2023Article
- Article
- High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Endometrial polyps are non-neoplastic but harbor epithelial mutations in endometrial cancer drivers at low allelic frequencies.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 3 countries.
Funding
Abstract
Uterine adenosarcomas (UAs) are biphasic lesions composed of a malignant mesenchymal (ie stromal) component and an epithelial component. UAs are generally low-grade and have a favourable prognosis, but may display sarcomatous overgrowth (SO), which is associated with a worse outcome. We hypothesized that, akin to breast fibroepithelial lesions, UAs are mesenchymal neoplasms in which clonal somatic genetic alterations are restricted to the mesenchymal component. To characterize the somatic genetic alterations in UAs and to test this hypothesis, we subjected 20 UAs to a combination of whole-exome (n = 6), targeted capture (n = 13) massively parallel sequencing (MPS) and/or RNA sequencing (n = 6). Only three genes, FGFR2, KMT2C and DICER1, were recurrently mutated, all in 2/19 cases; however, 26% (5/19) and 21% (4/19) of UAs harboured MDM2/CDK4/HMGA2 and TERT gene amplification, respectively, and two cases harboured fusion genes involving NCOA family members. Using a combination of laser-capture microdissection and in situ techniques, we demonstrated that the somatic genetic alterations detected by MPS were restricted to the mesenchymal component. Furthermore, mitochondrial DNA sequencing of microdissected samples revealed that epithelial and mesenchymal components of UAs were clonally unrelated. In conclusion, here we provide evidence that UAs are genetically heterogeneous lesions and mesenchymal neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.